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Abstract
Objective Obesity is associated with a variety of chronic
diseases, including cancer, which may partly be explained
by its influence on sex steroid hormone concentrations.
Whether different measures of obesity, i.e., body mass
index (BMI), waist circumference, and percent body fat
were differentially associated with circulating levels of sex
steroid hormones was examined in 1,265 men, aged
20–90? years old, attending the morning examination
session of the Third National Health and Nutrition Exam-
ination Survey (NHANES III).
Materials and methods Serum hormones were measured
by immunoassay. Weight, height, and waist circumference
were measured by trained staff. Percent body fat was
estimated from bioelectrical impedance. Multivariate linear
regression was used to estimate associations between body
fatness measures and hormone levels.
Results Total and free testosterone and sex hormone
binding globulin concentrations decreased, whereas total
and free estradiol increased with increasing BMI, waist
circumference, and percent body fat (all p trend \ 0.05).
The magnitude of change in these hormones was similar
for a one-quartile increase in each body fatness measure.
Conclusion Measured BMI, waist circumference, and
percent body fat led to similar inferences about their
association with hormone levels in men.
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Introduction
Obesity is a growing problem in Western countries,
including the United States, and an emerging problem in
Asian countries [1]. Obesity leads to health consequences,
including a higher risk of type 2 diabetes mellitus, heart
disease, cancer [2, 3], and premature death overall and
from cardiovascular disease and cancer [4]. The precise
mechanisms by which obesity influences chronic disease
risk are not entirely clear yet, but one line of evidence
involves changes in circulating levels of sex steroid hor-
mones and sex hormone binding globulin (SHBG) with
obesity, particularly with respect to cancer [5]. More body
fat leads to a higher conversion of testosterone to estradiol
by aromatase in fat tissue [6]. This increased conversion
suppresses luteinizing hormone release [7, 8], which results
in a reduced production of testosterone by the Leydig cells.
Estrogens also inhibit the activity of 17-a-hydroxylase and
17, 20 lyase, thus, inhibiting intratesticular steroidogenesis
[9]. High insulin levels in obese men may inhibit hepatic
SHBG production in HepG2 cells [10].
Most studies that examined the association between
obesity and circulating sex steroid hormone levels have
relied on either body mass index (BMI) or waist circum-
ference (or waist-to-hip ratio) as indicators of body fatness.
The association between percentage of body fat and cir-
culating steroid hormone levels has been less well studied.
Although these three measures are correlated, they do
reflect different aspects of obesity [11]. Thus, the aims of
this study were (a) to estimate the associations between
three measures of body fatness with serum sex steroid
concentrations overall and after taking into account factors
that are both associated with hormones and body fatness,
and (b) to assess differences in the magnitude of the
associations between different measures of body fatness
and hormones in a nationally representative sample of US
men.
Materials and methods
Study population
The Third National Health and Nutrition Examination
Survey (NHANES III) is a cross-sectional study that was
conducted by the National Center for Health Statistics
between 1988 and 1994. It is based on a multistage strat-
ified, clustered probability sample of the US civilian non-
institutionalized population at least 2 months old [12].
Specific sub-groups of the US population, including Mex-
ican–Americans, non-Hispanic blacks, and the elderly,
were over-sampled to ensure minimum sample sizes.
NHANES III was conducted in two phases (1988–1991 and
1991–1994) and unbiased national estimates of health and
nutrition characteristics can be independently produced for
each of these two phases. Within each phase, subjects were
randomly assigned to participate in either the morning or
afternoon/evening examination session. More than 33,000
subjects participated in NHANES III. Of these, 1,998 men
at least 20 years of age participated in the morning session
of phase I. Morning sample participants were chosen for
this hormone study to reduce extraneous variation due to
diurnal production of hormones. For the purpose of our
study, serum samples for hormone measurements were still
available for 1,470 of these men. Men with a history of
prostate cancer were excluded because certain treatments
may have affected hormone levels (n = 12). We further
excluded 193 men due to missing information on BMI
(n = 1), waist circumference (n = 47), percent body fat
(n = 94), and other covariates (n = 6). Sixteen men were
excluded for having missing hormone measurements and
an additional 29 men were excluded for having extreme
hormone measurements. The following cut-points were
used to determine extreme hormone measurements and are
based on visual inspection of the distribution of each hor-
mone on the natural log scale: ln(testosterone) B 0.4 (1.5%
ile), ln (free testosterone) B -4.0 (1.4% ile), ln (free
estradiol) B -1.5 (0.15% ile), ln(SHBG) B 1.7 (0.08%
ile), and ln (AAG) B 2.0 (0.5% ile), leaving 1,265 men for
the final analyses.
Subjects participated in an interview that was conducted
at home and in an extensive physical examination, which
included a blood sample collection. Cigarette smoking,
alcohol consumption, and physical activity were assessed
using a questionnaire. Height was measured to the nearest
0.1 cm using a stadiometer and weight was measured to the
nearest 0.01 kg using an electronic digital scale while the
participant was wearing foam slippers and paper shirt and
pants. BMI was calculated as weight in kilograms divided
by the square of height in meters. Waist circumference was
measured at the iliac crest to the nearest 0.1 cm. A Valhalla
Scientific Body Composition Analyzer (model 1990B;
Valhalla Scientific, Inc., San Diego, CA) was used to
measure whole body electrical resistance. Validated pre-
diction equations using height and weight were used to
convert whole body electrical resistance at 50 kHz to
percent body fat [13].
Measurement of serum sex steroid hormones
and SHBG
Blood was drawn after an overnight fast for participants in
the morning sample during either an examination at a med-
ical examination center or during an abbreviated examina-
tion at home. After centrifugation, serum was aliquoted and
stored at -70C until they pulled from the freezers for this
1142 Cancer Causes Control (2011) 22:1141–1151
123
project. The serum samples were shipped on dry ice directly
from the National Center for Health Statistics’ main repos-
itory in Atlanta, GA, to the assay laboratory.
Serum hormone concentrations were measured in the
laboratory of Dr. Nader Rifai at Children’s Hospital in
Boston, MA. Competitive electrochemiluminescence
immunoassays on the 2010 Elecsys autoanalyzer (Roche
Diagnostics, Indianapolis, IN) were used to quantify serum
testosterone, estradiol, and SHBG. Androstanediol glucu-
ronide was measured by an enzyme immunoassay (Diag-
nostic Systems Laboratories, Webster, TX). The participant
samples were randomly ordered for testing and the labora-
tory technicians were blinded to the identities and charac-
teristics of the participants. The lowest detection limits of the
assays were: testosterone 0.02 ng/ml, estradiol 5 pg/ml,
androstanediol glucuronide 0.33 ng/ml, and SHBG 3 nmol/
l. The coefficients of variation for quality control specimens
included during the analyses of the NHANES III specimens
were as follows: testosterone 5.9 and 5.8% at 2.5 and 5.5 ng/
ml; estradiol 6.5 and 6.7% at 102.7 and 474.1 pg/ml;
androstanediol glucuronide 9.5 and 5.0% at 2.9 and 10.1 ng/
ml; and SHBG 5.3 and 5.9% at 5.3 and 16.6 nmol/l. In
addition, we ran quality control samples with a mean estra-
diol concentration of 39.4 pg/ml, which is in the range of
typical male estradiol concentrations; the intra-assay CV%
was 5.2% and the inter-assay CV% was 2.5%. Free testos-
terone concentration was estimated from measured total
testosterone, SHBG, and albumin (already available in the
NHANES III public use database) [14]; free estradiol was
calculated from total estradiol, SHBG, and albumin [15].
Statistical analysis
All statistical analyses were performed using SUDAAN
[16] as implemented in SAS v.9.1 (Cary, NC). Sampling
weights were applied to take into account selection prob-
abilities, over-sampling, non-response, and differences
between the sample and the total US population [12].
We computed the Spearman correlation coefficient
adjusted for age between the different hormones. Linear
regression models were used to estimate the association
between quartiles of the three measures of body fatness—
BMI, waist circumference, and percent body fat—and
hormone concentrations. Because hormone and SHBG
concentrations were not normally distributed, we used log-
transformed data. In Model 1, we adjusted for age (1 year
increments) and race/ethnicity (non-Hispanic black, non-
Hispanic white, Mexican–American, other). To evaluate
the possibly confounding effects of factors that influence
hormone concentrations, in Model 2, we included age and
race/ethnicity as well as cigarette smoking (never smoker,
former smoker, current smoker), alcohol consumption
(never drinker, B1 drink/week,[1 drink/week to\1 drink/
day, 1? drink/day), and physical activity (moderate or
vigorous physical activity on 0 times/week,\3 times/week,
C3 to\8 times/week,[8 times/week). When Model 2 was
further adjusted for serum cotinine and a spline term for
age at 42 years, the inferences did not significantly change;
therefore, we did not include these factors in the final
Model 2. In Model 3, we adjusted for the factors in Model
2 plus mutually adjusted testosterone, estradiol, and SHBG
because these hormones compete for binding with SHBG,
and adjusted free testosterone for total estradiol and free
estradiol for total testosterone. We compared geometric
mean concentrations of hormones and SHBG across
quartiles of BMI, waist circumference, and percent body
fat using analysis of variance. We estimated the slope of
the change in the natural logarithm hormone concentration
with increasing body fatness by entering into the models an
ordinal variable with values of 1, 2, 3, and 4 corresponding
to quartile of each body fatness measure; we tested its
coefficient using the Wald test. We used quartiles to
compare the strengths of the association using a compa-
rable scaling of each body fat measure; one unit change in
BMI, waist circumference, and percent body fat are not
comparable in scale, but taking the distribution of these fat
measures, which each captures extent of body fatness, and
dividing them based on achieving equal numbers of men
should yield approximately comparable scaling.
While each of the three anthropometric measures
reflects the underlying extent of body fat, each is measured
with error, although the sources of errors may not be the
same. Thus, we cross-classified the men based on quartiles
of 2 of the 3 body fatness measures at a time and estimated
the geometric mean hormone concentrations for men in the
lowest quartile on both of the measures, the highest quartile
on both of the measures, and all other combinations. We
then compared the geometric means for the combinations
to the means for the individual measures.
Finally, we computed the changes in BMI, waist cir-
cumference, and percent body fat that were associated with
a 2% decline in the geometric mean of total testosterone,
free testosterone, total estradiol, free estradiol, SHBG, and
androstanediol glucuronide. These estimates were calcu-
lated based on geometric mean hormone levels for a
50-year-old white man who is a non-smoker, in the second
quartile of alcohol consumption and physical activity.
All significance tests were two-sided; p \ 0.05 was
considered to be statistically significant.
The protocols for the conduct of NHANES III were
approved by the Institutional Review Board of the National
Center for Health Statistics, US Centers for Disease Con-
trol and Prevention. Informed consent was obtained from
all participants. The measurement of sex steroid hormones
in these stored serum specimens were approved by Insti-
tutional Review Boards at the Johns Hopkins Bloomberg
Cancer Causes Control (2011) 22:1141–1151 1143
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School of Public Health and the National Center for Health
Statistics, US Centers for Disease Control and Prevention.
Results
The distribution of baseline characteristics in the study
population after applying sampling weights is shown in
Table 1. The prevalence of current smoking was 34.0 and
17.4% of men consumed at least one alcoholic drink/day.
One-third of men had moderate or vigorous activity 8 or
more times/week; this included walking or stair climbing.
The prevalence of obesity was 17.4% based on BMI
(C30 kg/m2), 24.5% based on waist circumference
(C102 cm), and 48.8% based on percent body fat
(C25%; see [17]). The partial Spearman correlation coef-
ficients (adjusted for age and race/ethnicity) between the
three measures of body fatness were: BMI and waist
circumference: r = 0.93; BMI and percent body fat:
r = 0.68; and waist circumference and percent body fat:
r = 0.71.
Almost all hormones were statistically significantly
correlated, although the strength of correlation differed.
Correlation coefficients of total testosterone with free tes-
tosterone, total and free estradiol, androstanediol glucuro-
nide, and SHBG were 0.75, 0.43, 0.15, 0.11, 0.63,
respectively (all p values B 0.0001); correlation coeffi-
cients of free testosterone with total and free estradiol,
androstanediol glucuronide, and SHBG were 0.49, 0.47,
0.16, 0.06, respectively (all p values B 0.0001; SHBG:
p = 0.046); correlation coefficients of total estradiol with
free estradiol, androstanediol glucuronide, and SHBG were
0.89, 0.09, and 0.11, respectively (all p values B 0.0001;
androstanediol glucoronide p = 0.003); correlation coeffi-
cients of free estradiol with androstanediol glucuronide
and SHBG were 0.07 (p = 0.01) and -0.27 (p B 0.0001),
Table 1 Selected
characteristics and hormone
concentrations of 1,265 adult
men who participated in the
morning examination session of
Phase I of the third national
health and nutrition examination
survey (NHANES III)
SE standard error, IQR
interquartile range
a Sampling weights were
applied
b Geometric mean
Subject characteristics Unweighted
sample size
Mean or
percentage (SE)a
IQR
Age (years) 1,265 41.6 (0.7) 27–62
Race/ethnicity (%)
Non-hispanic white 590 78.6 (3.1)
Non-hispanic black 298 8.9 (1.3)
Mexican–American 326 5.0 (0.8)
Other 51 7.4 (2.1)
Body fat (%) 1,265 24.9 (0.3) 21.8–29.4
Body mass index (kg/m2) 1,265 26.3 (0.2) 22.7–28.7
Waist circumference (cm) 1,265 94.4 (0.6) 83.5–102.3
Cigarette smoking (%)
Never 433 34.5 (2.3)
Former 424 31.5 (2.9)
Current 408 34.0 (2.1)
Alcohol consumption (%)
0 drinks/month 461 30.6 (2.5)
0.1–4 drinks/month 224 17.0 (1.6)
4.1–29.9 drinks/month 372 35.0 (2.1)
C30 drinks/month 208 17.4 (2.6)
Frequency of physical activity (%)
0 times/week 162 8.0 (1.3)
0.1–2.9 times/week 388 29.3 (2.0)
3–7.9 times/week 357 29.8 (1.2)
C8 times/week 358 32.9 (2.9)
Total testosterone (ng/ml)b 1,265 5.59 (0.09) 3.8–6.5
Total estradiol (pg/ml)b 1,265 37.3 (0.7) 28.6–43.1
SHBG (nmol/L)b 1,265 37.7 (0.7) 26.1–51.5
Androstanediol glucuronide (ng/ml)b 1,265 14.4 (0.5) 7.0–15.9
Free testosterone (ng/ml)b 1,265 0.112 (0.002) 0.07–0.13
Free estradiol (pg/ml)b 1,265 0.962 (0.02) 0.71–1.1
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respectively; correlation between androstanediol glucuro-
nide and SHBG was 0.0007 (p value 0.98).
Total and free testosterone
Total and free testosterone concentrations decreased with
increasing extent of each body fatness measure (Tables 2,
3, 4). For total testosterone, the decline in concentration
with increasing body fatness was attenuated after further
adjustment for smoking, alcohol consumption, and physical
activity (Model 2) and was even more greatly attenuated
after further adjustment for total estradiol and SHBG
(Model 3). For free testosterone, the size of the decline in
concentration with increasing body fatness was similar in
Table 2 Sex steroid hormone and SHBG concentrations by quartiles of BMI in men, NHANES III, 1988–1991
BMI Model 1a Model 2b Model 3c
Quartile Range (kg/m2) Mean 95% CI Mean 95% CI Mean 95% CI
Total testosterone (ng/ml)
Q1 B22.9 6.16 (5.96, 6.37) 6.07 (5.85, 6.30) 5.55 (5.36, 5.75)
Q2 23.0–25.3 5.73 (5.49, 5.98) 5.64 (5.40, 5.88) 5.48 (5.33, 5.65)
Q3 25.4–28.7 5.13 (4.91, 5.37) 5.19 (4.96, 5.43) 5.35 (5.19, 5.53)
Q4 [28.7 4.28 (4.12, 4.44) 4.38 (4.23, 4.52) 4.74 (4.58, 4.91)
Slope, p trendd -0.12 \0.001 -0.11 \0.001 -0.05 \0.001
Free testosterone (ng/ml)
Q1 B22.9 0.11 (0.106, 0.114) 0.108 (0.104, 0.111) 0.109 (0.105, 0.113)
Q2 23.0–25.3 0.111 (0.106, 0.116) 0.109 (0.104, 0.115) 0.11 (0.106, 0.114)
Q3 25.4–28.7 0.106 (0.102, 0.110) 0.107 (0.102, 0.111) 0.108 (0.104, 0.112)
Q4 [28.7 0.097 (0.092, 0.101) 0.099 (0.095, 0.103) 0.096 (0.093, 0.100)
Slope, p trendd -0.04 0.001 -0.03 0.02 -0.04 0.002
Total estradiol (pg/ml)
Q1 B22.9 35.87 (34.29, 37.53) 35.3 (34.08, 36.57) 34.19 (32.69, 35.77)
Q2 23.0–25.3 36.2 (34.60, 37.87) 35.69 (34.19, 37.27) 34.95 (33.68, 36.28)
Q3 25.4–28.7 34.64 (32.79, 36.59) 35.16 (33.35, 37.07) 35.13 (33.51, 36.82)
Q4 [28.7 37.11 (35.62, 38.67) 37.64 (35.91, 39.45) 39.73 (38.05, 41.48)
Slope, p trendd 0.006 0.5 0.018 0.1 0.044 \0.001
Free estradiol (pg/ml)
Q1 B22.9 0.85 (0.81, 0.90) 0.84 (0.80, 0.87) 0.82 (0.78, 0.85)
Q2 23.0–25.3 0.9 (0.85, 0.95) 0.89 (0.85, 0.94) 0.88 (0.84, 0.93)
Q3 25.4–28.7 0.9 (0.85, 0.95) 0.91 (0.87, 0.96) 0.92 (0.88, 0.96)
Q4 [28.7 1.03 (0.98, 1.08) 1.04 (0.99, 1.10) 1.08 (1.03, 1.13)
Slope, p trendd 0.056 \0.001 0.066 \0.001 0.086 \0.001
Sex hormone binding globulin (nmol/l)
Q1 B22.9 43.38 (40.42, 46.55) 43.29 (40.50, 46.28) 38.59 (36.60, 40.69)
Q2 23.0–25.3 37.45 (35.17, 39.87) 36.89 (34.85, 39.05) 34.95 (33.35, 36.64)
Q3 25.4–28.7 32.52 (30.43, 34.77) 32.62 (30.46, 34.94) 32.88 (31.01, 34.88)
Q4 [28.7 26.71 (25.43, 28.05) 27.06 (25.71, 28.47) 31.75 (30.06, 33.54)
Slope, p trendd -0.16 \0.001 -0.15 \0.001 -0.07 \0.001
Androstanediol glucuronide (ng/ml)
Q1 B22.9 10.97 (10.02, 12.00) 10.98 (10.03, 12.02) Not applicable
Q2 23.0–25.3 12.45 (11.16, 13.90) 12.6 (11.34, 14.01)
Q3 25.4–28.7 12.49 (11.92, 13.09) 12.43 (11.72, 13.18)
Q4 [ 28.7 12.04 (10.93, 13.25) 11.98 (10.86, 13.21)
Slope, p trendd 0.028 0.1 0.026 0.2
a Model 1 adjusted for age and race/ethnicity
b Model 2 adjusted for age and race/ethnicity, smoking, alcohol consumption, physical activity
c Model 3 same as model 2 plus testosterone, estradiol, and SHBG mutually adjusted and free testosterone and free estradiol mutually adjusted
d Per 1 quartile change in BMI
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Models 1 and 3, but less steep in Model 2. In the fully
adjusted model (Model 3), the extent of the decline in total
testosterone and also in free testosterone concentrations
was similar for a one-quartile change in BMI (Table 2),
waist circumference (Table 3), and percent body fat
(Table 4).
Total and free estradiol
Total estradiol concentration did not increase with
increasing extents of any of the three measures of body
fatness after adjustment for age and race/ethnicity (Model
1). However, in the fully adjusted model (Model 3), total
Table 3 Sex steroid hormone and SHBG concentrations by quartiles of waist circumference in men, NHANES III, 1988–1991
Waist circumference Model 1a Model 2b Model 3c
Quartile Range (cm) Mean 95% CI Mean 95% CI Mean 95% CI
Total testosterone (ng/ml)
Q1 B84.9 6.48 (6.18, 6.79) 6.34 (6.01, 6.69) 5.65 (5.48, 5.83)
Q2 85.0–92.8 5.58 (5.36, 5.82) 5.55 (5.34, 5.77) 5.5 (5.31, 5.69)
Q3 92.9–101.7 5.01 (4.68, 5.35) 5.05 (4.77, 5.34) 5.26 (5.10, 5.43)
Q4 [101.7 4.26 (4.07, 4.47) 4.34 (4.14, 4.56) 4.73 (4.57, 4.90)
Slope, p trendd -0.14 \0.001 -0.12 \0.001 -0.06 \0.001
Free testosterone (ng/ml)
Q1 B84.9 0.114 (0.110, 0.117) 0.112 (0.108, 0.115) 0.111 (0.107, 0.115)
Q2 85.0–92.8 0.108 (0.104, 0.112) 0.108 (0.103, 0.112) 0.109 (0.105, 0.114)
Q3 92.9–101.7 0.104 (0.098, 0.111) 0.105 (0.099, 0.110) 0.106 (0.102, 0.110)
Q4 [101.7 0.097 (0.092, 0.101) 0.099 (0.094, 0.103) 0.097 (0.093, 0.100)
Slope, p trendd -0.05 \0.001 -0.04 0.001 -0.05 \0.001
Total estradiol (pg/ml)
Q1 B84.9 36.93 (35.44, 38.48) 36.31 (34.91, 37.76) 34.71 (33.18, 36.31)
Q2 85.0–92.8 35.02 (33.28, 36.85) 34.95 (33.41, 36.56) 34.4 (32.82, 36.05)
Q3 92.9–101.7 34.67 (32.19, 37.36) 35.02 (32.96, 37.22) 35.34 (33.72, 37.04)
Q4 [101.7 37.15 (35.51, 38.86) 37.49 (35.76, 39.29) 39.53 (38.23, 40.87)
Slope, p trendd 0.001 0.9 0.01 0.3 0.042 \0.001
Free estradiol (pg/ml)
Q1 B84.9 0.87 (0.82, 0.92) 0.86 (0.82, 0.90) 0.83 (0.78, 0.87)
Q2 85.0–92.8 0.87 (0.82, 0.92) 0.87 (0.83, 0.92) 0.86 (0.82, 0.91)
Q3 92.9–101.7 0.91 (0.84, 0.98) 0.92 (0.86, 0.98) 0.92 (0.87, 0.98)
Q4 [101.7 1.03 (0.99, 1.08) 1.04 (0.99, 1.09) 1.08 (1.04, 1.12)
Slope, p trendd 0.056 \0.001 0.063 \0.001 0.085 \0.001
Sex hormone binding globulin (nmol/l)
Q1 B84.9 45.42 (41.75, 49.42) 44.93 (41.38, 48.78) 38.98 (36.97, 41.10)
Q2 85.0–92.8 36.53 (34.30, 38.89) 36.27 (34.33, 38.32) 34.57 (33.11, 36.09)
Q3 92.9–101.7 31.75 (29.71, 33.94) 32.04 (29.92, 34.32) 32.92 (31.47, 34.44)
Q4 [101.7 26.66 (25.48, 27.88) 26.9 (25.76, 28.08) 31.66 (30.32, 33.05)
Slope, p trendd -0.17 \0.001 -0.17 \0.001 -0.07 \0.001
Androstanediol glucuronide (ng/ml)
Q1 B84.9 10.52 (9.50, 11.65) 10.49 (9.47, 11.61) Not applicable
Q2 85.0–92.8 12.17 (11.23, 13.19) 12.22 (11.23, 13.29)
Q3 92.9–101.7 12.76 (11.86, 13.72) 12.72 (11.69, 13.84)
Q4 [101.7 12.6 (11.59, 13.71) 12.63 (11.54, 13.82)
Slope, p trendd 0.058 0.01 0.06 0.02
a Model 1 adjusted for age and race/ethnicity
b Model 2 adjusted for age and race/ethnicity, smoking, alcohol consumption, physical activity
c Model 3 same as model 2 plus testosterone, estradiol, and SHBG mutually adjusted and free testosterone and free estradiol mutually adjusted
d Per 1 quartile change in waist circumference
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estradiol statistically significantly increased with increas-
ing BMI (Table 2) and waist circumference (Table 3). For
percent body fat (Table 4), we observed a statistically
significant increasing association after adjusting for the
modifiable factors (Model 2), and an even stronger
increasing association after further adjusting for total
testosterone and SHBG (Model 3). In Model 3, the slope of
the increase in total estradiol concentration with increasing
body fatness was similar for BMI, waist circumference, and
percent body fat. Free estradiol concentration increased
with increasing extent of body fatness in all three models;
the slope of the increase was greatest for Model 3 and was
Table 4 Sex steroid hormone and SHBG concentrations by quartiles of percent body fat in men, NHANES III, 1988–1991
Percent body fat Model 1a Model 2b Model 3c
Quartile Range (%) Mean 95% CI Mean 95% CI Mean 95% CI
Total testosterone (ng/ml)
Q1 B21.4 6.06 (5.77, 6.37) 5.95 (5.66, 6.25) 5.49 (5.28, 5.71)
Q2 21.5–24.9 5.63 (5.33, 5.95) 5.62 (5.35, 5.90) 5.54 (5.35, 5.74)
Q3 25.0–28.6 5.12 (4.90, 5.36) 5.15 (4.94, 5.37) 5.34 (5.22, 5.47)
Q4 [28.6 4.42 (4.18, 4.68) 4.5 (4.27, 4.74) 4.75 (4.57, 4.94)
Slope, p trendd -0.1 \0.001 -0.09 \0.001 -0.05 \0.001
Free testosterone (ng/ml)
Q1 B21.4 0.109 (0.106, 0.113) 0.108 (0.104, 0.112) 0.109 (0.104, 0.114)
Q2 21.5–24.9 0.111 (0.104, 0.118) 0.11 (0.104, 0.117) 0.111 (0.106, 0.115)
Q3 25.0–28.6 0.107 (0.103, 0.111) 0.107 (0.104, 0.111) 0.108 (0.104, 0.111)
Q4 [28.6 0.096 (0.091, 0.101) 0.097 (0.093, 0.102) 0.095 (0.091, 0.100)
Slope, p trendd -0.04 0.011 -0.03 0.006 -0.04 0.001
Total estradiol (pg/ml)
Q1 B21.4 35.52 (33.82, 37.30) 35.09 (33.61, 36.64) 34.3 (32.46, 36.23)
Q2 21.5–24.9 35.48 (33.06, 38.08) 35.59 (33.69, 37.60) 34.74 (33.28, 36.27)
Q3 25.0–28.6 35.69 (33.52, 38.01) 35.59 (33.82, 37.45) 35.52 (33.95, 37.15)
Q4 [28.6 37 (35.58, 38.48) 37.45 (35.94, 39.02) 39.33 (37.67, 41.06)
Slope, p trendd 0.013 0.145 0.02 0.03 0.043 0.001
Free estradiol (pg/ml)
Q1 B21.4 0.85 (0.81, 0.90) 0.85 (0.81, 0.89) 0.83 (0.79, 0.88)
Q2 21.5–24.9 0.89 (0.83, 0.96) 0.89 (0.84, 0.95) 0.89 (0.84, 0.94)
Q3 25.0–28.6 0.93 (0.87, 1.00) 0.93 (0.88, 0.98) 0.93 (0.89, 0.98)
Q4 [28.6 1 (0.95, 1.05) 1.01 (0.97, 1.05) 1.03 (0.99, 1.09)
Slope, p trendd 0.051 \0.001 0.057 \0.001 0.071 \0.001
Sex hormone binding globulin (nmol/l)
Q1 B21.4 42.73 (39.74, 45.95) 42.18 (39.54, 45.00) 37.83 (36.30, 39.42)
Q2 21.5–24.9 35.87 (34.56, 37.23) 35.84 (34.73, 36.98) 33.89 (32.58, 35.24)
Q3 25.0–28.6 31.63 (29.53, 33.87) 31.91 (29.80, 34.18) 32.46 (30.97, 34.02)
Q4 [28.6 28.99 (27.12, 30.99) 29.14 (27.37, 31.02) 33.75 (32.20, 35.38)
Slope, p trendd -0.13 \0.001 -0.12 \0.001 -0.04 0.003
Androstanediol glucuronide (ng/ml)
Q1 B21.4 10.6 (9.67, 11.62) 10.56 (9.65, 11.56) Not applicable
Q2 21.5–24.9 12.52 (11.48, 13.64) 12.57 (11.39, 13.86)
Q3 25.0–28.6 12.16 (11.37, 13.00) 12.24 (11.43, 13.11)
Q4 [28.6 12.73 (11.68, 13.88) 12.64 (11.62, 13.75)
Slope, p trendd 0.052 0.019 0.052 0.03
a Model 1 adjusted for age and race/ethnicity
b Model 2 adjusted for age and race/ethnicity, smoking, alcohol consumption, physical activity
c Model 3 same as model 2 plus testosterone, estradiol, and SHBG mutually adjusted and free testosterone and free estradiol mutually adjusted
d Per 1 quartile change in percent body fat
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comparable for BMI (Table 2), waist circumference
(Model 3), and percent body fat (Model 4).
SHBG
SHBG concentration decreased with increasing extent of
each measure of body fatness in all models (Tables 2, 3, 4).
The extent of the decline in concentration was similar
for Models 1 and 2, but was attenuated after additional
adjustment for total testosterone and total estradiol (Model
3). In Model 3, the extent of the decline was similar for
BMI (Table 2) and waist circumference (Table 3), but less
steep for percent body fat (Table 4).
Androstanediol glucuronide
For each measure of body fatness, androstanediol glucuronide
concentration was lowest in the bottom quartile and equally
high in the top three quartiles. The associations were the same
for Models 1 and 2. The slope of the increase in concentration
was higher and statistically significant for waist circumfer-
ence (Table 3) and percent body fat (Table 4) only.
For each hormone and SHBG, we examined whether the
patterns differed by age; however, the patterns were gen-
erally similar across age (data not shown).
When we cross-classified the men by quartiles of any
two of the body fatness measures, the geometric mean
hormone concentrations for men in the top quartile of two
of the measures and for men in the bottom quartile of two
of the measures were similar to the geometric mean con-
centrations when using only one of the measures (data not
shown).
Finally, we estimated how much the men’s BMIs, waist
circumferences, and percent body fat would have to differ to
result in a 2% lower geometric mean hormone concentra-
tions (Table 5). Lower total and free testosterone and SHBG
concentrations were observed among men with higher body
fatness, whereas lower total and free estradiol and andro-
stanediol glucuronide concentrations were observed among
men with lower body fatness. Body fatness was most
strongly associated with total testosterone and SHBG con-
centrations such that a higher BMI of less than 1 kg/m2, a
higher waist circumference of approximately 2 cm, or a 1%
higher body fat percentage would result in a 2% lower geo-
metric mean concentration of these two analytes.
Discussion
We evaluated the associations between body fatness and
circulating concentrations of sex steroid hormones and
SHBG in a nationally representative sample of US men
20? years old. We used three measures of body fatness:
BMI, waist circumference, and percent body fat. BMI is the
most often used measure of body fatness because it is easy
to assess. However, it is an imperfect indicator of extent of
fat mass because BMI captures both fat and lean mass.
Although BMI tends to stay constant with age, lean body
mass declines and fat mass increases [18, 19]. Thus, in
younger men, a high BMI is more likely to reflect lean
body mass than in older men [19]. Nevertheless, BMI is a
strong predictor of cardiovascular, total cancer, and all
cause mortality [20]. Waist circumference is considered to
be a good indicator of central adiposity and, thus, intra-
abdominal fat mass [21], and it has been shown to be a
better predictor of cardiovascular disease risk than waist-
to-hip ratio in men [22]. Additionally, in the European
Prospective Investigation into Cancer and Nutrition
(EPIC), it has been shown that both general adiposity and
abdominal adiposity were associated with the risk of death,
but also supported the use of waist circumference or WHR
in addition to BMI in assessing the risk of death [4]. The
third indicator that we used in this study was the percentage
of total mass that is fat mass. Percent body fat is less fre-
quently used in epidemiologic studies because its mea-
surement requires specialized equipment and is more labor
intensive [11]. These three measures reflect different
aspects of obesity [11], yet are correlated. Thus, our goal
was to examine in detail and compare their associations
with hormone levels.
We observed a decrease in total testosterone concen-
tration with increasing body fatness, which is consistent
with previous studies that used either BMI, waist
Table 5 Change in BMI, waist circumference, and percent body fat
associated with a 2% decline in the geometric mean concentration of
total testosterone, free testosterone, total estradiol, free estradiol,
SHBG and androstanediol glucuronide in men, NHANES III,
1988–1991
Change in body fatnessa
BMI
(kg/
m2)
Waist
circumference
(cm)
Percent
body fat (%)
Total testosterone 0.8 2.0 1.1
Free testosterone 2.3 5.2 2.7
Total estradiol -4.3 -14.9 -5.1
Free estradiol -1.4 -3.7 -1.8
SHBG 0.7 1.6 0.9
Androstanediol
glucuronide
-6.7 -7.3 -1.9
a Estimates are calculated based on the geometric mean testosterone
concentration for a 50-year-old white man who is a non-smoker, in
the second quartile of alcohol consumption and physical activity
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circumference, or, in some instances, percent body fat [18,
23–28]. Adjustment for smoking, alcohol drinking, and
physical activity, each of which is associated with hormone
levels [29], slightly reduced the slope of the decline in
concentration for each body fatness measure. Because body
fatness and testosterone are both associated with estradiol
and SHBG, further adjustment for estradiol and SHBG
produced a substantial attenuation of the slope. The slopes
of the declines in total testosterone concentration were
comparable for each of the three measures of body fatness.
Free testosterone concentration also declined with all three
measures of body fatness and the extent of the decline was
similar across all three measures. Only a slight attenuation
was observed after further adjustment for smoking, alcohol,
and physical activity and further adjustment for total
estradiol enhanced the slopes. The slope of the decline after
adjustment for age and race/ethnicity was less steep than
for total testosterone. However, after multivariable adjust-
ment, including total estradiol, the slopes for free and total
testosterone were comparable. These results suggest that
investigators should consider taking into account other
modifiable risk factors and other hormones when studying
the links among body fatness, total testosterone, and
chronic diseases.
We observed an increase in total estradiol concentration
with increasing BMI, waist circumference, and percent
body fat primarily after taking into account testosterone
and SHBG concentrations, both of which are correlates of
estradiol and body fatness. The magnitude of the increase
in total estradiol concentration was about the same for each
measure of body fatness after multivariable adjustment.
Each measure of body fatness was associated with free
estradiol; the association was enhanced with multivariable
adjustment. Although it is well recognized that aromatase
in fat tissue catalyzes the conversion of testosterone to
estradiol [6], not all studies that have evaluated the extent
of body fatness and circulating estradiol have observed a
direct association. Vermeulen et al. [30] reported higher
estradiol concentrations in obese European men (age
25–62 years) compared with non-obese men, but no asso-
ciation was observed in an Italian study [23]. Muller et al.
[31] observed a statistically significant increase in estradiol
concentration over quartiles of BMI and waist circumfer-
ence; this study adjusted for age, smoking, alcohol con-
sumption, physical activity, and the presence of chronic
diseases. In a US study, estradiol was not statistically
associated with body fat or waist circumference in middle-
aged men [32] and no association has been observed
in other US studies [25, 33]. A Greek study reported a
77% higher estradiol concentration in elderly men with
BMI C 30 compared with BMI \ 27 kg/m2, although this
difference was of marginal statistical significance [34]. One
reason for differences among studies might be that studies
did not consistently adjust for confounding factors; our
results suggest that taking into account testosterone and
SHBG are needed to observe a clear association between
body fatness and total estradiol.
An inverse association between obesity and SHBG has
been reported consistently [23, 24, 26–28, 33, 35]. Some
studies have observed associations for BMI and/or waist
circumference but not fat mass [18, 25, 32]. We observed
inverse associations between each of the three measures of
body fatness and SHBG. For each, the association was
substantially attenuated after taking into account total tes-
tosterone and total estradiol; the association was weakest
for percent body fat, although it remained statistically
significant. It might be that SHBG is more strongly affected
by abdominal than overall obesity.
Androstanediol glucuronide is a dihydrotestosterone
metabolite that is considered an indicator of testosterone to
dihydrotestosterone conversion by 5-alpha-reductases. We
observed a non-linear association between the measures of
body fatness and androstanediol glucuronide concentration;
levels were equally higher in the top three quartiles of each
measure of body fatness. However, the magnitude of the
association was weaker and not significant for BMI. This
latter result is compatible with previous studies that did not
find associations between BMI and blood levels of andro-
stanediol glucuronide [33, 36], although high BMI was
related to higher levels of androstanediol glucuronide in
male EPIC participants [37]. Based on their own and the
observations of another study [38], Suzuki et al. [37]
hypothesized that excess body weight might stimulate
peripheral androgen metabolism, while lowering overall
testosterone concentrations.
To get a better sense of just how large of a change in
each measure of body fatness would be necessary to yield
the same magnitude of change in any given hormone
concentration and to determine which hormones are more
greatly affected by body fatness for the purpose of
assessing public health impact, we estimated the change in
each of the measures of body fatness that would yield a 2%
change in the geometric mean hormone concentration.
Total testosterone and SHBG concentrations were higher
with slightly lower BMI, waist circumference, and percent
body fat, implying that even a modest loss of body fat
could improve testosterone and SHBG profiles. In contrast,
big decreases in body fatness would be needed to reduce
total estradiol and androstanediol glucuronide.
The strengths of our study include the standardized
measurement of the three measures of body fatness, the
measurement of hormone levels with good precision, and
the availability of modifiable correlates of hormones in a
large, well-characterized group of men who are represen-
tative of the general US population. Limitations of our
study include the cross-sectional nature of the association
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such that we cannot determine whether body fatness affects
hormones or vice versa, and the single measurement hor-
mone levels, which may not represent the men’s usual
levels.
In conclusion, our results suggest that measured BMI,
waist circumference, and percent body fat lead to similar
inferences about the association between body fatness and
hormone levels in men. Investigators should use whichever
of the measures of body fatness that is most feasible for
their study and is appropriate for the outcome (for example,
if diabetes is the outcome, the investigators may be most
interested in measuring waist circumference). Additionally,
investigators should consider taking into account other
modifiable risk factors and other hormones when studying
the links among body fatness, total testosterone or SHBG,
and chronic diseases.
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